In HR+ breast cancer, the activation of PI3K pathway by PIK3CA mutation promotes ligand-independent ER activation, which is one of the important mechanisms of endocrine therapy resistance [53,58,59,60]. This evidence concerns the gene PIK3CD and breast carcinoma.